nach oben

Erschienen in:

01.12.2014 | Original Paper

ACT2 Peer-Driven Intervention Increases Enrollment into HIV/AIDS Medical Studies Among African Americans/Blacks and Hispanics: A Cluster Randomized Controlled Trial

verfasst von: Marya Gwadz, Charles M. Cleland, Mindy Belkin, Amanda Ritchie, Noelle Leonard, Marion Riedel, Angela Banfield, Pablo Colon, Vanessa Elharrar, Jonathan Kagan, Donna Mildvan, ACT2 Collaborative Research Team

Erschienen in: AIDS and Behavior | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

African American/Black and Hispanic persons living with HIV/AIDS (“AABH-PLHA”) are under-represented in HIV/AIDS medical studies (HAMS). This paper evaluates the efficacy of a social/behavioral intervention to increase rates of screening for and enrollment into HAMS in these populations. Participants (N = 540) were enrolled into a cluster randomized controlled trial of an intervention designed to overcome multi-level barriers to HAMS. Primary endpoints were rates of screening for and enrollment into therapeutic/treatment-oriented and observational studies. Intervention arm participants were 30 times more likely to be screened than controls (49.3 % vs. 3.7 %; p < .001). Half (55.5 %) of those screened were eligible for HAMS, primarily observational studies. Nine out of ten found eligible enrolled (91.7 %), almost all into observational studies (95.2 %), compared to no enrollments among controls. Achieving appropriate representation of AABH-PLHA in HAMS necessitates modification of study inclusion criteria to increase the proportion found eligible for therapeutic HAMS, in addition to social/behavioral interventions.

Castillo-Mancilla J, Cohn S, Krishnan S, et al. Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials. HIV Clin Trials. 2014;15(1):14–26.PubMedCrossRef

National Institute of Allergy and Infectious Diseases [NIAID]. HIV infection in minority populations 2008. http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/PopulationSpecificInformation/Pages/minorityPopulations.aspx. Accessed 31 July 2013.

Ortiz AP, Colon-Lopez V, Girona-Lozada G, et al. Report of the 2012 Capacity building for HIV-HPV clinical trials recruitment among minority underserved populations of Hispanic origin in Puerto Rico. P R Health Sci J. 2012;31(3):185–7.PubMedCentralPubMed

Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med. 2002;346(18):1373–82.PubMedCrossRef

Gwadz MV, Colon P, Ritchie AS, et al. Increasing and supporting the participation of persons of color living with HIV/AIDS in AIDS clinical trials. Curr HIV/AIDS Rep. 2010;7(4):194–200.PubMedCentralPubMedCrossRef

Menezes P, Eron JJ, Leone PA, Adimora AA, Wohl DA, Miller WC. Recruitment of HIV/AIDS treatment-naive patients to clinical trials in the highly active antiretroviral therapy era: influence of gender, sexual orientation and race. HIV Med. 2011;12(3):183–91.PubMedCentralPubMedCrossRef

Gwadz MV, Leonard NR, Cleland CM, et al. The effect of peer-driven intervention on rates of screening for AIDS clinical trials among African Americans and Hispanics. Am J Public Health. 2011;101(6):1096–102.PubMedCentralPubMedCrossRef

Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis. 2007;196(2):304–12.PubMedCrossRef

Wojna V, Skolasky RL, Hechavarria R, et al. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol. 2006;12(5):356–64.PubMedCrossRef

10.

McLaren PJ, Ripke S, Pelak K, et al. Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet. 2012;21(19):4334–47.PubMedCentralPubMedCrossRef

11.

Bacon MC, von Wyl V, Alden C, et al. The Women’s Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol. 2005;12(9):1013–9.PubMedCentralPubMed

12.

Corbie-Smith G, Odeneye E, Banks B, Shandor Miles M, Roman Isler M. Development of a multilevel intervention to increase HIV clinical trial participation among rural minorities. Health Educ Behav. 2013;40(3):274–85.PubMedCentralPubMedCrossRef

13.

Freedberg KA, Sullivan L, Georgakis A, Savetsky J, Stone V, Samet JH. Improving participation in HIV clinical trials: impact of a brief intervention. HIV Clin Trials. 2001;2(3):205–12.PubMedCrossRef

14.

Gwadz M, Cleland CM, Leonard NR, et al. Predictors of screening for AIDS clinical trials among African-Americans and Latino/Hispanics enrolled in an efficacious peer-driven intervention: uncovering socio-demographic, health, and substance use-related factors that promote or impede screening. AIDS Behav. 2013;17(2):801–12.PubMedCentralPubMedCrossRef

15.

Gwadz MV, Leonard NR, Nakagawa A, et al. Gender differences in attitudes toward AIDS clinical trials among urban HIV-infected individuals from racial and ethnic minority backgrounds. AIDS Care. 2006;18(7):786–94.PubMedCrossRef

16.

Russell SL, Katz RV, Wang MQ, et al. Belief in AIDS origin conspiracy theory and willingness to participate in biomedical research studies: findings in whites, blacks, and Hispanics in seven cities across two surveys. HIV Clin Trials. 2011;12(1):37–47.PubMedCentralPubMedCrossRef

17.

Stone VE, Mauch MY, Steger K, Janas SF, Craven DE. Race, gender, drug use, and participation in AIDS clinical trials. Lessons from a municipal hospital cohort. J Gen Intern Med. 1997;12(3):150–7.PubMedCentralPubMed

18.

Durant RW, Legedza AT, Marcantonio ER, Freeman MB, Landon BE. Different types of distrust in clinical research among Whites and African Americans. J Natl Med Assoc. 2011;103(2):123–30.PubMedCentralPubMed

19.

Sullivan PS, McNaghten AD, Begley E, Hutchinson A, Cargill VA. Enrollment of racial/ethnic minorities and women with HIV in clinical research studies of HIV medicines. J Natl Med Assoc. 2007;99(3):242–50.PubMedCentralPubMed

20.

Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med. 2006;3(2):e19.PubMedCentralPubMedCrossRef

21.

Simoni JM, Huh D, Wilson IB, et al. Racial/ethnic disparities in ART adherence in the United States: findings from the MACH14 study. J Acquir Immune Defic Syndr. 2012;60(5):466–72.PubMedCentralPubMedCrossRef

22.

Kyser M, Buchacz K, Bush TJ, et al. Factors associated with non-adherence to antiretroviral therapy in the SUN study. AIDS Care. 2011;23(5):601–11.PubMedCrossRef

23.

Feinberg J, Saag M, Squires K, et al. Health-related quality of life in the gender, race, and clinical experience trial. AIDS Res Treat. 2011;2011:349165.PubMedCentralPubMed

24.

Anastasi JK, Capili B, Kim GH, Chung A. Clinical trial recruitment and retention of a vulnerable population: HIV patients with chronic diarrhea. Gastroenterol Nurs. 2005;28(6):463–8.PubMedCrossRef

25.

Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 1997;50(4):385–91.PubMedCrossRef

26.

Freeman HP. Patient navigation: a community based strategy to reduce cancer disparities. J Urban Health. 2006;83(2):139–41.PubMedCentralPubMedCrossRef

27.

Bradford JB, Coleman S, Cunningham W. HIV system navigation: an emerging model to improve HIV care access. AIDS Patient Care STDS. 2007;21(Suppl 1):S49–58.PubMed

28.

Broadhead RS, Volkanevsky VL, Rydanova T, et al. Peer-driven HIV interventions for drug injectors in Russia: first year impact results of a field experiment. Intl J Drug Policy. 2006;17(5):379–92.CrossRef

29.

Flay BR, Snyder F, Petraitis J. The theory of triadic influence. In: DiClimente RJ, Kegler MC, Crosby RA, editors. Emerging theories in health promotion practice and research. New York: Jossey-Bass; 2009.

30.

Heckathorn DD. Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997;44(2):174–99.CrossRef

31.

Miller W, Rollnick S. Motivational interviewing: preparing people for change. 2nd ed. New York: Guilford; 2002.

32.

Leonard NR, Banfield A, Riedel M, et al. Description of an efficacious behavioral peer-driven intervention to reduce racial/ethnic disparities in AIDS clinical trials. Health Educ Res. 2013;28(4):574–90.PubMedCentralPubMedCrossRef

33.

Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):834–40.PubMedCrossRef

34.

Engel S, Cleland CM. The experience of screening for HIV/AIDS medical studies among African-American/Black and Latino/Hispanic persons living with HIV/AIDS: a mixed-methods exploration. J AIDS Clin Res. 2013;4:223.CrossRef

35.

Gandhi M, Ameli N, Bacchetti P, et al. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols. AIDS. 2005;19(16):1885–96.PubMedCrossRef

36.

Marshak A, Costantini G, Middleton S, et al. Screening for AIDS clinical trials in the project ACT cohort of racial/ethnic minorities and women in New York City: substantial interest but low eligibility. In: 4th International AIDS Society Conference, Sydney; 2007.

37.

Hays RD, Spritzer KL, McCaffrey D, et al. The HIV cost & services utilization study (HCSUS) measures of health-related quality of life. Santa Monica: Rand; 1998.

38.

Derogatis L, Melisaratos N. The brief symptom inventory: an introductory report. Psychol Med. 1983;13:595–605.PubMedCrossRef

39.

Des Jarlais DC, Friedman SR, Novick DM, et al. HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987. JAMA. 1989;261(7):1008–112.PubMedCrossRef

40.

Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull. 1971;76:378–82.CrossRef

41.

Albert A, Anderson A. On the existence of maximum likelihood estimates in logistic regression models. Biometrika. 1984;71:1–10.CrossRef

42.

Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80:27–38.CrossRef

43.

Fay MP. Two-sided exact tests and matching confidence intervals for discrete data. R J. 2010;2(1):53–8.

44.

Burger JM. The foot-in-the-door compliance procedure: a multiple-process analysis and review. Pers Soc Psychol Rev. 1999;3(4):303–25.PubMedCrossRef

45.

Gwadz MV, Cylar K, Leonard NR, et al. An exploratory behavioral intervention trial to improve rates of screening for AIDS clinical trials among racial/ethnic minority and female persons living with HIV/AIDS. AIDS Behav. 2010;14(3):639–48.PubMedCrossRef

46.

Penberthy L, Brown R, Wilson-Genderson M, Dahman B, Ginder G, Siminoff LA. Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment. Clin Trials. 2012;9(6):788–97.PubMedCrossRef

47.

Collins LM, Baker TB, Mermelstein RJ, et al. The multiphase optimization strategy for engineering effective tobacco use interventions. Ann Behav Med. 2011;41(2):208–26.PubMedCentralPubMedCrossRef

48.

Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat Med. 2005;24(10):1455–81.PubMedCrossRef

49.

Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy S. A “SMART” design for building individualized treatment sequences. Ann Rev Clin Psychol. 2012;8:21–48.CrossRef

50.

Hall HI, Frazier EL, Rhodes P, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44.PubMedCrossRef

51.

Torian LV, Wiewel EW. Continuity of HIV-related medical care, New York City, 2005–2009: do patients who initiate care stay in care? AIDS Patient Care STDS. 2011;25(2):79–88.PubMedCrossRef

Titel: ACT2 Peer-Driven Intervention Increases Enrollment into HIV/AIDS Medical Studies Among African Americans/Blacks and Hispanics: A Cluster Randomized Controlled Trial
verfasst von: Marya Gwadz
Charles M. Cleland
Mindy Belkin
Amanda Ritchie
Noelle Leonard
Marion Riedel
Angela Banfield
Pablo Colon
Vanessa Elharrar
Jonathan Kagan
Donna Mildvan
ACT2 Collaborative Research Team
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 12/2014
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-014-0829-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

15.04.2024 | Inkretinmimetika | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

ACT2 Peer-Driven Intervention Increases Enrollment into HIV/AIDS Medical Studies Among African Americans/Blacks and Hispanics: A Cluster Randomized Controlled Trial

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Fast jeder zehnte Magen bei Endoskopie noch nicht entleert

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Blutdrucksenkung per Spritze additiv zur Standardtherapie wirksam

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2014

Development of the Scale of Perceived Social Support in HIV (PSS-HIV)

Anticipated and Actual Reactions to Receiving HIV Positive Results Through Self-Testing Among Gay and Bisexual Men

Are Hormonal Contraceptive Users More Likely to Misreport Unprotected Sex? Evidence From a Biomarker Validation Study in Zimbabwe

Sexual Motivation, Sexual Transactions and Sexual Risk Behaviors in Men who have Sex with Men in Dar es Salaam, Tanzania

Loss to Follow-Up in a Cohort of HIV-Infected Patients in a Regional Referral Outpatient Clinic in Brazil

Systematic Assessment of Condom Use Measurement in Evaluation of HIV Prevention Interventions: Need for Standardization of Measures

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Fast jeder zehnte Magen bei Endoskopie noch nicht entleert

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie

Blutdrucksenkung per Spritze additiv zur Standardtherapie wirksam

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Innere Medizin